Suppr超能文献

公众对中国大陆基因治疗使用的态度。

Public Attitudes About the Use of Gene Therapy in Mainland China.

机构信息

Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

School of Health Policy and Management, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

JAMA Netw Open. 2023 Aug 1;6(8):e2328352. doi: 10.1001/jamanetworkopen.2023.28352.

Abstract

IMPORTANCE

In addition to technical barriers, public attitudes about the use of gene therapy have an important association with the clinical implementation of gene therapy.

OBJECTIVE

To investigate the factors associated with public acceptance of gene therapy among individuals in China.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from a survey conducted among 21 880 individuals in mainland China from June 20 to August 31, 2022.

MAIN OUTCOMES AND MEASURES

Stepwise linear regression was used to analyze factors associated with public acceptance of gene therapy in 5 key areas: basic personal information (gender, region, age, and educational level), family situation (marital status, children, and cousins), economic status (assets, debts, and insurance coverage), health knowledge (health literacy score and media use), and physical health status (chronic illness, cancer, European Quality of Life 5-Dimension 5-Level version [EQ-5D-5L] score, and Brief Illness Perception Questionnaire [BIPQ] score). Acceptance scores were calculated based on a visual analog scale (range, 0-100, with higher scores indicating higher acceptance of gene therapy). Further subgroup analysis was carried out in different age subgroups and populations with or without chronic diseases.

RESULTS

A total of 21 880 participants (mean [SD] age, 39.4 [18.9] years; 10 947 female participants [50.0%]; 10 933 male participants [50.0%]) were analyzed in this study. The mean (SD) acceptance score of gene therapy in the survey was 60.56 (27.60). Compared with people aged 60 years or older, those aged 12 to 18 years had higher acceptance of gene therapy (β = 1.48 [95% CI, 0.09-2.88]), while groups aged 19 to 30 years (β = -3.43 [95% CI, -4.80 to -2.07]), 31 to 44 years (β = -1.44 [95% CI, -2.76 to -0.12]), and 45 to 59 years (β = -2.05 [95% CI, -3.27 to -0.83]) had lower acceptance. Compared with people living in Eastern China, those in Central China had lower acceptance of gene therapy (β = -1.58 [95% CI, -2.54 to -0.62]), while those in Western China had higher acceptance (β = 0.92 [95% CI, 0.09-1.76]). Higher educational level (undergraduate or above vs junior high or below) was associated with higher acceptance of gene therapy (β = 1.56 [95% CI, 0.49-2.63]). Number of properties owned was also associated with higher acceptance of gene therapy (2 vs 0: β = 2.38 [95% CI, 1.04-3.72]; ≥3 vs 0: β = 4.66 [95% CI, 2.92-6.39]). Diagnosis of chronic disease was associated with lower acceptance of gene therapy (β = -17.86 [95% CI, -20.49 to -15.24]), while diagnosis of cancer was associated with higher acceptance (β = 6.99 [95% CI, 1.84-12.14]). Higher BIPQ score (β = 0.40 [95% CI, 0.34-0.45]), higher health literacy score (β = 0.70 [95% CI, 0.62-0.78]), and media use (β = 0.49 [95% CI, 0.41-0.57]) were all associated with high acceptance of gene therapy, while a higher EQ-5D-5L score was associated with lower acceptance (β = -0.29 [95% CI, -0.47 to -0.11]). For older people, being in debt, not having health insurance, and the EQ-5D-5L score were uniquely relevant factors. For people with chronic disease, having an undergraduate degree or higher, a diagnosis of cancer, and the BIPQ score were uniquely relevant factors.

CONCLUSIONS AND RELEVANCE

These results suggest that basic personal information, economic status, health knowledge, and physical health status were the main factors associated with the acceptance of gene therapy. Improving the health literacy of the population and promoting trust in gene therapy may be effective ways to increase the acceptance of gene therapy. Poorer economic levels and worse disease states may reduce the public's willingness to accept gene therapy.

摘要

重要性

除了技术障碍外,公众对基因治疗的态度与基因治疗的临床实施有重要关联。

目的

调查中国个体对基因治疗的接受程度的相关因素。

设计、设置和参与者:本横断面研究使用了 2022 年 6 月 20 日至 8 月 31 日期间在中国大陆进行的一项调查中 21880 名个体的数据。

主要结果和措施

采用逐步线性回归分析了 5 个关键领域与公众对基因治疗接受程度相关的因素:基本个人信息(性别、地区、年龄和教育水平)、家庭状况(婚姻状况、子女和表亲)、经济状况(资产、负债和保险覆盖范围)、健康知识(健康素养评分和媒体使用)和身体健康状况(慢性病、癌症、欧洲五维健康量表 5 维度版本[EQ-5D-5L]评分和简要疾病感知问卷[BIPQ]评分)。接受程度评分基于视觉模拟量表(范围为 0-100,分数越高表示对基因治疗的接受程度越高)。在不同年龄组和有无慢性病的人群中进行了进一步的亚组分析。

结果

在这项研究中,共分析了 21880 名参与者(平均[标准差]年龄,39.4[18.9]岁;女性参与者 10947 名[50.0%];男性参与者 10933 名[50.0%])。调查中基因治疗的平均(标准差)接受程度评分为 60.56(27.60)。与 60 岁及以上的人群相比,12 至 18 岁的人群对基因治疗的接受程度更高(β=1.48[95%CI,0.09-2.88]),而 19 至 30 岁(β=-3.43[95%CI,-4.80 至-2.07])、31 至 44 岁(β=-1.44[95%CI,-2.76 至-0.12])和 45 至 59 岁(β=-2.05[95%CI,-3.27 至-0.83])的人群对基因治疗的接受程度较低。与居住在华东地区的人群相比,居住在华中地区的人群对基因治疗的接受程度较低(β=-1.58[95%CI,-2.54 至-0.62]),而居住在西部地区的人群对基因治疗的接受程度较高(β=0.92[95%CI,0.09-1.76])。较高的教育水平(本科及以上与初中及以下)与对基因治疗的较高接受程度相关(β=1.56[95%CI,0.49-2.63])。拥有的房产数量也与对基因治疗的较高接受程度相关(2 套与 0 套:β=2.38[95%CI,1.04-3.72];≥3 套与 0 套:β=4.66[95%CI,2.92-6.39])。诊断患有慢性病与对基因治疗的较低接受程度相关(β=-17.86[95%CI,-20.49 至-15.24]),而诊断患有癌症与对基因治疗的较高接受程度相关(β=6.99[95%CI,1.84-12.14])。较高的 BIPQ 评分(β=0.40[95%CI,0.34-0.45])、较高的健康素养评分(β=0.70[95%CI,0.62-0.78])和媒体使用(β=0.49[95%CI,0.41-0.57])均与对基因治疗的较高接受程度相关,而较高的 EQ-5D-5L 评分与较低的接受程度相关(β=-0.29[95%CI,-0.47 至-0.11])。对于老年人,负债、没有健康保险和 EQ-5D-5L 评分是唯一相关的因素。对于患有慢性病的人群,拥有本科及以上学历、患有癌症和 BIPQ 评分是唯一相关的因素。

结论和相关性

这些结果表明,基本个人信息、经济状况、健康知识和身体健康状况是与基因治疗接受程度相关的主要因素。提高人口的健康素养并促进对基因治疗的信任可能是增加基因治疗接受程度的有效途径。较差的经济状况和较差的疾病状况可能会降低公众对基因治疗的意愿。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa26/10422191/f34fd08b4b69/jamanetwopen-e2328352-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验